Article
Dual STAT3/STAT5 inhibition as a novel treatment strategy in T-prolymphocytic leukemia.
Leukemia - 1 Jun 2025
Dechow Annika, Timonen Sanna, Ianevski Aleksandr, Jiang Qu, Wahnschaffe Linus, Peng Yayi, Jungherz Dennis, Becker Kerstin, Neubauer Heidi A, Schönefeldt Susann, de Araujo Elvin, Gunning Patrick, Fleck Roman, Schrader Alexandra, Hallek Michael, Pflug Natali, Moriggl Richard, Aittokallio Tero, Mustjoki Satu, Braun Till, Herling Marco
Abstract excerpt
T-prolymphocytic leukemia (T-PLL) is a rare, aggressive T-cell malignancy with poor outcomes and an urgent need for new therapeutic approaches. Integrating genomic data and new transcriptomic profiling, we identified recurrent JAK/STAT mutations (predominantly in JAK3 and STAT5B) as hallmarks in a cohort of 335 T-PLL cases. In line, transcriptomic and protein analyses revealed constitutive JAK/STAT activation in...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.